Spondyloarthropathies News

Tuesday, March 25, 2008 Diagnosis Delay in Patients with Ankylosing Spondylitis
Researchers have established new diagnostic criteria for ankylosing spondylitis in an effort to minimize the diagnosis delay in AS...

Tuesday, January 15, 2008 Evaluation of a Quantitative Scoring of Enthesitis in Ankylosing Spondylitis
Researchers assessed the validity of an enthesitis index calculated by algometric pressure pain threshold scoring...

Tuesday, November 13, 2007 Anti-IL-12/23 Monoclonal Produces Dramatic Results in Psoriatic Arthritis
The anti-IL-12/23 monoclonal antibody ustekinumab produced dramatic, durable improvements in psoriatic arthritis, according to phase II data reported at the American College of Rheumatology...

Friday, November 09, 2007 Efalizumab Suspected of Triggering Arthritis in Subset of Psoriasis Patients
A small subset of patients treated with efalizumab for severe plaque psoriasis developed new-onset psoriatic arthritis...

Thursday, November 08, 2007 Centocor, Schering-Plough's Anti-TNF Golimumab Significantly Improved Articular, Skin, and Nail Manifestations in Patients With Psoriatic Arthritis in Phase III Study; Met Primary and Major Secondary Endpoints
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that patients with active psoriatic arthritis (PsA) receiving monthly subcutaneous injections of golimumab experienced significant and sustained improvements in the joint and skin manifestations of the disease, according to findings from the largest phase III biologic study (GO-REVEAL trial) in PsA subjects...

Thursday, November 08, 2007 Centocor, Schering-Plough's Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of AS in Phase III Study; Monthly Treatment Yielded Marked Improvements in Physical Function
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that more than half of patients receiving monthly subcutaneous injections of golimumab 50 mg and 100 mg experienced significant and sustained improvements in the signs and symptoms of active ankylosing spondylitis (AS), according to the phase III study (GO-RAISE trial) results...

Thursday, September 27, 2007 Panel Issues New Guidelines for Use of Imaging in Ankylosing Spondylitis
Although standard X-rays are essential for diagnosis and MRI may help diagnose early cases before radiographic damage develops,  no form of imaging is yet useful for monitoring response to treatment or for routine monitoring of disease progression in AS, experts say...

Friday, September 21, 2007  TNF Blockade Slows But Does Not Stop X-Ray Progression in AS
Four-year follow-up data show that infliximab slows but does not inhibit radiographic progression in AS…

Tuesday, September 11, 2007 Synovio-Entheseal Complex Seen As Key to Psoriatic Arthritis, Spondylarthropathies
The synovio-entheseal complex (SEC), where the enthesis and synovium come together in a synovial joint, links joint damage and innate immune activation leading to joint inflammation...McGonagle D, et al. Arthritis Rheum. 2007;56:2482-2491.

Thursday, August 23, 2007 NICE Issues Positive Appraisal of Abbott's Humira® (adalimumab) for the Treatment of Psoriatic Arthritis in UK Patient Population 
The National Institute for Health and Clinical Excellence has published final guidance on the use of Humira® (adalimumab, Abbott Laboratories), a recombinant human monoclonal antibody that binds specifically to TNF-a, for the treatment of psoriatic arthritis (PsA)...